We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Sandoz Says An Eli Lilly ADHD Drug Patent Is Invalid

Law360 (August 29, 2007, 12:00 AM EDT) -- Sandoz Inc. has launched a preemptive strike against Eli Lilly & Co., asking a New Jersey court to declare that an Eli Lilly patent relating to attention-deficit drug Strattera is invalid and not infringed by a Sandoz-proposed drug.

Sandoz, the U.S.-based generics arm of Novartis AG, filed the declaratory judgment suit against Eli Lilly on Monday, in the U.S. District Court for the District of New Jersey.

At issue is U.S. Patent Number 5,658,590, entitled “Treatment of attention-deficit/hyperactivity disorder,” issued in 1997 and assigned to Eli...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.